vTv Therapeutics

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 85.71% and -99.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates

HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

Celsion

Zosano Pharma

These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.

3 Biopharma Penny Stocks That Could be Millionaire Makers

HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden.

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737

Adial Pharmaceuticals Inc

MediciNova

Intec Parent

OPKO Health

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top 10 Biotech Penny Stocks to Watch in July 2021

Bio-Path Holdings

Moderna

Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna announced that the European Commission has purchased an additional 150 million doses of COVID-19 vaccine.

Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today

Privately-held Cantex Pharmaceuticals Inc has entered into a licensing agreement with vTv Therapeutics Inc (NASDAQ: VTVT) to develop and commercialize vTv's azeliragon. Under the terms of the agreement, Cantex will be responsible for the development and commercialization of azeliragon, and the companies will allocate downstream profits under a tiered arrangement.

vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings

HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel antagonist of RAGE (the receptor for advanced glycation endproducts).

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

Amesite Operating

Orphazyme A/S

Support.com

Wondering what penny stocks are? Here's your answer and 4 to watch The post What Are Penny Stocks?

What Are Penny Stocks? 4 to Buy [Or Sell] In 2021

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -50.00% and 23.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

Arrival Group

Pubmatic

Schrodinger 

vTv Therapeutics, Arrival, PubMatic, and Schrodinger are four up-and-coming stocks to buy. All four are benefiting from rapidly shifting trends.

4 Up-and-Coming Stocks to Buy in Shifting Sectors

The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.

vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug

Today, VTVT stock is on the move as investors price in a key announcement from the FDA designating a leading drug a breakthrough therapy. The post VTVT Stock: The FDA News Sending vTv Therapeutics Soaring Today appeared first on InvestorPlace.

VTVT Stock: The FDA News Sending vTv Therapeutics Soaring Today

The stock price of vTv Therapeutics Inc. (Nasdaq: VTVT) increased by over 10% pre-market. This is why it happened.

VTVT Stock: Over 15% Increase Pre-Market Explanation

Designation offers potential for expedited development pathway and reinforces TTP399's potential to provide a substantial clinical benefit Designation offers potential for expedited development pathway and reinforces TTP399's potential to provide a substantial clinical benefit

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported SimpliciT-1 Study will be presented at A Scientific Symposium: In celebration of the 100th anniversary of the University of Toronto's discovery of insulin (Insulin100) held virtually, April 15 & 16, 2021.

TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399

HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. The phase 1 study will test the hypothesis that treatment with vTv's TTP399, a liver-selective glucokinase activator, will not result in the increased production of ketones, a precursor to ketoacidosis, which can lead to hospitalization in patients with type 1 diabetes.

vTv Therapeutics Announces Initiation of Study Evaluating TTP399's Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C. Wainwright Global Life Sciences Conference held virtually March 9-10, 2021.

vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Initiation of Mechanistic Study of TTP399 expected during Q1 2021

vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021

vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

The stock price of vTv Therapeutics Inc (NASDAQ: VTVT) is trading at over 30% as of 4:38 AM ET today. This is why it happened.

VTVT Stock Price Increases Over 30% Pre-Market: Why It Happened

HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci Partners 10th Annual Healthcare Corporate Access Event held virtually from January 11-14 2021.

News for vTv Therapeutics Stock (VTVT)